Centre Hospitalier de Lens Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3

Organization Overview

First Clinical Trial
2006
NCT00832234
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Centre Hospitalier de Lens | Hospital of Lens

Active Ingredients

Drugs in Phase 3 Trials (1)

nicotinamide (1 trial)

Drugs in Phase 2 Trials (4)

bortezomib (velcade) (1 trial)

lenalidomide (revlimid) (1 trial)

rituximab (rituxan) (1 trial)

urea (1 trial)

Drugs in Phase 1 Trials (1)

red blood cells (1 trial)

Drugs in Other Trials (1)

landiolol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 3)

Shock (Phase 3)

Shock, Septic (Phase 3)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 7